Jaguar Animal Health, Inc. JAGX
7.70
0.64
9.07%
as of 25 Sep
- Market cap
- $3.8M
- P/E
- 0.1×
Follow JAGX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.37 |
P/S ratio |
4.49 | 2.83 | 3.40 | 1.31 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(11.30) | (5.94) | 11.38 | (6.82) | |
P/B ratio |
28.26 | 0.00 | 0.00 | 7.40 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.19 | 3.81 | 3.57 | 1.28 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(2.35) | (1.85) | (13.99) | (5.32) | |
EV/FCF |
(2.29) | (1.80) | (12.82) | (4.83) | |
Quick Ratio |
0.14 | 0.23 | 0.25 | 0.27 | |
Current Ratio |
0.81 | 0.50 | 0.50 | 0.69 | |
Net Debt/EBITDA |
(0.62) | (0.35) | 0.09 | 0.73 | |
Debt/Assets |
15.46% | 39.36% | 29.59% | 5.05% | |
Debt/Equity |
1.75 | (0.81) | (0.70) | 0.35 | |
Asset Turnover |
0.22 | 0.25 | 0.67 | 0.67 | |
Operating CF/Net income |
0.49 | 0.24 | (1.26) | 0.42 | |
Capex/Depreciation |
(0.10) | (0.06) | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
118.65% | 442.44% | 19.38% | 272.33% | |
Selling, General and Administrative Expense of Revenue |
198.86% | 221.45% | 24.68% | 363.67% | |
Intangible Assets out of Total Assets |
0.35 | 0.42 | 0.42 | 0.44 | |
Share Based Compensation of Revenue |
4.38% | 3.59% | 0.76% | 13.96% | |
Graham Net Nets |
(0.30) | (1.12) | (0.33) | (0.32) | |
Graham Number |
0.00 | 2,379.49 | 390.93 | 128.48 | |
Earnings Yield |
(138.94%) | (162.19%) | (114.19%) | 268.05% | |
Free Cash Flow Yield |
(50.35%) | (74.76%) | (8.19%) | (20.25%) | |
Revenue per Share |
71.20 | 48.50 | 39.30 | 1.51 | |
Operating CF per Share |
(108.29) | (82.28) | 17.12 | (6.60) | |
Capex per Share |
(1.25) | (0.61) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(109.54) | (82.89) | 17.12 | (6.60) | |
Cash per Share |
81.46 | 117.42 | 19.51 | 8.14 | |
Shareholders Equity per Share |
100.67 | (280.18) | (30.54) | 6.08 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
100.67 | (280.18) | (30.54) | 6.08 | |
Free Cash Flow |
(4.74) | (5.53) | 8.83 | (5.34) | |
Working Capital |
(6.72) | (20.31) | (20.48) | (7.85) | |
Capital Expenditures |
(0.05) | (0.04) | — | — | |
Net Current Asset Value |
(15.71) | (36.67) | (32.98) | (11.74) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.01 | 0.00 | 0.00 | |
Net Profit Margin |
(308.21%) | (717.22%) | (34.60%) | (1,036.82%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.41 | 1.67 | 0.83 | 0.76 | |
Average Payables |
6.50 | 6.99 | 5.99 | 5.71 | |
Average Inventory |
10.15 | 9.47 | 9.19 | 9.02 | |
Average Assets |
53.97 | 45.87 | 44.45 | 41.23 | |
Average Common Equity |
7.49 | (7.34) | (7.46) | 4.66 |
Columns are period end dates